Phase II study of pseudomonas aeruginosa-mannose-sensitive hemagglutinin in combination with capecitabine for HER2-negative metastatic breast cancer pretreated with anthracycline and taxane.

Authors

Fangfang Lv

Fudan University Shanghai Cancer Center, Shanghai, China

Fangfang Lv , Jun Cao , Zhebin Liu , Zhong Hua Wang , Jian Zhang , Sheng Zhang , Leiping Wang , Xinmin Zhao , Shao Zhimin , Biyun Wang , Xi-Chun Hu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2012 ASCO Annual Meeting

bookmark_border

Final analysis of phase II study of EZN-2208 (PEG-SN38) in metastatic breast cancer (MBC).

First Author: Cynthia R. C. Osborne

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane.

First Author: Lee S. Schwartzberg

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs. treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC).

First Author: Debu Tripathy

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study.

First Author: Andrew David Seidman